DE3856017D1 - Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit - Google Patents

Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit

Info

Publication number
DE3856017D1
DE3856017D1 DE3856017T DE3856017T DE3856017D1 DE 3856017 D1 DE3856017 D1 DE 3856017D1 DE 3856017 T DE3856017 T DE 3856017T DE 3856017 T DE3856017 T DE 3856017T DE 3856017 D1 DE3856017 D1 DE 3856017D1
Authority
DE
Germany
Prior art keywords
disease
levels
hormones
alzheimer
senile dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3856017T
Other languages
English (en)
Other versions
DE3856017T2 (de
Inventor
Chaovanee Aroonsakul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AROONSAKUL, CHAOVANEE, SAN ANTONIO, TEX., US
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3856017D1 publication Critical patent/DE3856017D1/de
Publication of DE3856017T2 publication Critical patent/DE3856017T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
DE3856017T 1988-01-11 1988-01-11 Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit Expired - Fee Related DE3856017T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88100233A EP0324037B1 (de) 1988-01-11 1988-01-11 Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit

Publications (2)

Publication Number Publication Date
DE3856017D1 true DE3856017D1 (de) 1997-10-09
DE3856017T2 DE3856017T2 (de) 1998-04-23

Family

ID=8198634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856017T Expired - Fee Related DE3856017T2 (de) 1988-01-11 1988-01-11 Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit

Country Status (5)

Country Link
EP (1) EP0324037B1 (de)
AT (1) ATE157546T1 (de)
DE (1) DE3856017T2 (de)
ES (1) ES2109914T3 (de)
GR (1) GR3025576T3 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149786A (en) * 1989-10-12 1992-09-22 Chiron Corporation Dopamine releasing protein and antibody
IT9041720A1 (it) * 1990-10-26 1992-04-27 Fidia Spa Metodo per la diagnosi del parkinson idiopatico
WO1994022469A1 (en) * 1993-04-02 1994-10-13 Ohio University Enhancement of learning and/or memory by a human somatotropin
SE9804064D0 (sv) * 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
EP1502593B1 (de) * 2003-07-29 2007-02-14 Acme S.R.L. Verwendung von Stanozolol zur Herstellung von entzündungshemmenden und antidegenerativen Arzneimitteln

Also Published As

Publication number Publication date
ES2109914T3 (es) 1998-02-01
GR3025576T3 (en) 1998-03-31
DE3856017T2 (de) 1998-04-23
EP0324037B1 (de) 1997-09-03
EP0324037A1 (de) 1989-07-19
ATE157546T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
Hoyer et al. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases
Wittling et al. Neuroendocrine hemisphere asymmetries: salivary cortisol secretion during lateralized viewing of emotion-related and neutral films
De Volder et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration
Hunter et al. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication
EP0276723B1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins
Duffau et al. Intraoperative unmasking of brain redundant motor sites during resection of a precentral angioma: evidence using direct cortical stimulation
Yasuhara et al. Lack of exercise, via hindlimb suspension, impedes endogenous neurogenesis
Gibb et al. Pathological report of four patients presenting with cranial dystonias
Lauria et al. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies
Sachar et al. Human growth hormone response to levodopa: Relation to menopause, depression, and plasma dopa concentration
Oren et al. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder
Esmonde et al. Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases.
Brod et al. Combination therapy with glatiramer acetate (copolymer‐1) and a type I interferon (IFN‐α) does not improve experimental autoimmune encephalomyelitis
Linkowski et al. The 24-hour profile of plasma prolactin in men with major endogenous depressive illness
Gadoth et al. Episodic hormone secretion during sleep in Kleine-Levin syndrome: evidence for hypothalamic dysfunction
Korenke et al. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters
Souetre et al. The circadian rhythm of plasma thyrotropin in depression and recovery
De Reuck et al. A double‐blind study of neurotropin in patients with acute ischemic stroke
Sandyk et al. Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders
Dubé et al. A Metabolic and Neuropathological Approach to the Understanding of Plastic Changes That Occur in the Immature and Adult Rat Brain During Lithium‐Pilocarpine–Induced Epileptogenesis
DE3856017D1 (de) Verwendung von Anabolika zur Herstellung eines Arzneimittels zur Behandlung von seniler Dementia und der Alzheimerschen Krankheit
Fois et al. Giant axonal neuropathy. Endocrinological and histological studies
Jennekens-Schinkel et al. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man
JP2850128B2 (ja) 老化度測定方法
Dvořák Plasma 17-hydroxycorticosteroid levels in healthy and diarrhoeic calves

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AROONSAKUL, CHAOVANEE, SAN ANTONIO, TEX., US

8339 Ceased/non-payment of the annual fee